Systematic Financial Management LP reduced its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,390 shares of the company’s stock after selling 1,572 shares during the quarter. Systematic Financial Management LP’s holdings in Omnicell were worth $6,857,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently made changes to their positions in OMCL. New York State Common Retirement Fund grew its holdings in Omnicell by 4.0% during the 2nd quarter. New York State Common Retirement Fund now owns 39,000 shares of the company’s stock valued at $1,681,000 after buying an additional 1,499 shares in the last quarter. Vanguard Group Inc. grew its holdings in Omnicell by 3.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock valued at $83,105,000 after buying an additional 67,902 shares in the last quarter. State Street Corp grew its holdings in Omnicell by 5.8% during the 2nd quarter. State Street Corp now owns 898,871 shares of the company’s stock valued at $38,739,000 after buying an additional 49,026 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Omnicell by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,880 shares of the company’s stock valued at $1,202,000 after buying an additional 605 shares in the last quarter. Finally, Fisher Asset Management LLC grew its holdings in Omnicell by 7.5% during the 3rd quarter. Fisher Asset Management LLC now owns 528,919 shares of the company’s stock valued at $27,001,000 after buying an additional 36,717 shares in the last quarter.
In related news, CFO Peter J. Kuipers sold 1,926 shares of the firm’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $51.69, for a total value of $99,554.94. Following the completion of the transaction, the chief financial officer now directly owns 40,544 shares of the company’s stock, valued at $2,095,719.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 3.77% of the company’s stock.
Omnicell, Inc. (NASDAQ OMCL) opened at $44.20 on Friday. Omnicell, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $55.40. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.73 and a quick ratio of 1.28. The firm has a market cap of $1,651.96, a price-to-earnings ratio of 86.67, a P/E/G ratio of 3.59 and a beta of 0.65.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 1st. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.02. Omnicell had a net margin of 2.88% and a return on equity of 1.54%. The firm had revenue of $198.26 million during the quarter, compared to analyst estimates of $205.50 million. During the same period last year, the firm posted $0.37 earnings per share. Omnicell’s revenue for the quarter was up 13.6% compared to the same quarter last year. research analysts predict that Omnicell, Inc. will post 0.77 EPS for the current year.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Piper Jaffray Companies increased their price objective on shares of Omnicell from $38.00 to $44.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Craig Hallum lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $63.00 price objective on shares of Omnicell in a report on Thursday, February 1st. Finally, Oppenheimer reissued a “buy” rating and issued a $55.00 target price on shares of Omnicell in a report on Monday, January 29th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $56.14.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/02/23/omnicell-inc-omcl-shares-sold-by-systematic-financial-management-lp.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.